![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/JUBLPHARMA.png)
Share the post "Jubilant Pharmova ‘s Q3 2024-25 Latest News: Profit Grows by 320.83% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 11.87 % in the past year, substantial increase in net sales/revenue by 18.29 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -3.16 %, Marginal decrease of -57.99% in other income during this quarter. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Jubilant Pharmova Limited. Profit dropped by -320.83 % Year to Year, Jubilant Pharmova Limited’s profitability dropped by -49.52 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -320.00 % Year to Year. EPS decreased by -50 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 175.2 Cr | Rs. 165.7 Cr | Rs. 196 Cr | + 18.29 % | + 11.87 % |
| Expenses | Rs. 175.9 Cr | Rs. 171.8 Cr | Rs. 185 Cr | + 7.68 % | + 5.17 % |
| Operating Profit | Rs. -0.7 Cr | Rs. -6.1 Cr | Rs. 11 Cr | + 280.33 % | + 1671.43 % |
| OPM % | -0.4 % | -3.68 % | 5.61 % | + 9.29 % | + 6.01 % |
| Other Income | Rs. 19 Cr | Rs. 43.8 Cr | Rs. 18.4 Cr | -57.99 % | -3.16 % |
| Interest | Rs. 8.3 Cr | Rs. 7.8 Cr | Rs. 7.4 Cr | -5.13 % | -10.84 % |
| Depreciation | Rs. 12.3 Cr | Rs. 13.3 Cr | Rs. 13.3 Cr | + 0 % | + 8.13 % |
| Profit before tax | Rs. -2.3 Cr | Rs. 16.6 Cr | Rs. 8.7 Cr | -47.59 % | + 478.26 % |
| Tax % | -4.35 % | 36.75 % | 39.08 % | + 2.33 % | + 43.43 % |
| Net Profit | Rs. -2.4 Cr | Rs. 10.5 Cr | Rs. 5.3 Cr | -49.52 % | + 320.83 % |
| EPS in Rs | Rs. -0.15 | Rs. 0.66 | Rs. 0.33 | -50 % | + 320 % |
Today, we’re looking at Jubilant Pharmova Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 11.87 %. However, it did see a marginal increase of 18.29 % from the previous quarter. Expenses ticked up slightly by 7.68 % quarter-on-quarter, aligning with the annual rise of 5.17 %. Operating profit, while up 1671.43 % compared to last year, faced a quarter-on-quarter increase of 280.33 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 6.01 %, but an expansion of 9.29 % sequentially. Other income fell by -57.99 % compared to the last quarter, despite an annual decline of -3.16 %. Interest expenses dropped significantly by -5.13 % from the previous quarter, yet the year-over-year decrease remains at a moderate -10.84 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 8.13 %. Profit before tax grew annually by 478.26 % but saw a reduction from the preceding quarter by -47.59 %.
Tax expenses as a percentage of profits increased slightly by 43.43 % compared to last year, with a more notable quarter-on-quarter increase of 2.33 %. Net profit rose by 320.83 % year-on-year but witnessed a -49.52 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 320 % but a quarterly fall of -50 %. In summary, Jubilant Pharmova Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 175.2 Cr | Rs. 165.7 Cr | Rs. 196 Cr | + 18.29 % | + 11.87 % |
| Expenses | Rs. 175.9 Cr | Rs. 171.8 Cr | Rs. 185 Cr | + 7.68 % | + 5.17 % |
| Operating Profit | Rs. -0.7 Cr | Rs. -6.1 Cr | Rs. 11 Cr | + 280.33 % | + 1671.43 % |
| Net Profit | Rs. -2.4 Cr | Rs. 10.5 Cr | Rs. 5.3 Cr | -49.52 % | + 320.83 % |
| EPS in Rs | Rs. -0.15 | Rs. 0.66 | Rs. 0.33 | -50 % | + 320 % |
In reviewing Jubilant Pharmova Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 11.87 % year-on-year growth, however, there was a minor increase of 18.29 % from the previous quarter. Expenses rose by 5.17 % compared to the previous year, with a 7.68 % increase quarter-on-quarter. Operating Profit surged by 1671.43 % annually, and saw a 280.33 % increase from the last quarter.
Net Profit showed yearly increase of 320.83 %, and experienced a -49.52 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 320 % annually, however dipped by -50 % compared to the last quarter. In essence, while Jubilant Pharmova Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
